Nordic Nanovector: European Patent Granted for Betalutin or Humalutin in Combination With Anti-CD20 Antibodies for Treating NHL
04-Jun-2019 -
Nordic Nanovector ASA announces that the European Patent Organisation (EPO) has granted the company's European Patent covering the use of Betalutin® or Humalutin® in combination with anti-CD20 antibodies for the treatment of non-Hodgkin's lymphoma (NHL). The same patent has also been issued in ...
antibodies
non-Hodgkin lymphoma
patents